Last10K.com

Urologix Inc (ULGX) SEC Filing 10-K Annual report for the fiscal year ending Monday, June 30, 2014

Urologix Inc

CIK: 882873 Ticker: ULGX

Exhibit 99.1

 

 

August 19, 2014

For Immediate Release

Urologix Reports Fourth Quarter and Fiscal Year 2014 Results

Recent Highlights

Urologix restructured the company in April 2014 which reduced cash utilization in the fourth quarter to $98,000
Cost-effectiveness data covering Cooled ThermoTherapyTM presented at 2014 AUA Annual Meeting in May

 

MINNEAPOLIS — August 19, 2014— Urologix®, Inc. (OTCQB: ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today reported financial results for its fourth quarter and fiscal year ended June 30, 2014. The Company also announces that Brian Smrdel, Chief Financial Officer, resigned due to personal reasons effective August 13, 2014. Greg Fluet has been appointed by the Board and has accepted the position of Interim CFO in addition to his current responsibilities as CEO until a suitable replacement is hired.

 

Fourth quarter fiscal year 2014 revenue totaled $3.3 million, down 2% sequentially from the third quarter of fiscal year 2014 and down 21% compared to the fourth quarter of fiscal year 2013. The sequential decrease in revenue was driven primarily by reduced sales of Cooled ThermoTherapyTM (CTT) products partially offset by a slight increase in Prostiva® products. The year-over-year decline in revenue was driven by a decline in sales of CTT and Prostiva products compared to the prior year.

 

“Urologix successfully completed a major restructuring of our business in the fourth quarter of fiscal year 2014. As part of this restructuring we deployed a new sales model that leverages a smaller field sales team by deploying inside sales resources and our mobile service to deliver on our commitment to patients and meeting our urology customers’ needs. The team demonstrated this commitment by delivering on our sales plan for the quarter resulting in minimal cash utilization”, stated Greg Fluet, Chief Executive Officer. “Our goal is to end fiscal year 2015 with positive cash flow from operations and build upon the recent data presented at the AUA on the cost-effectiveness of our in-office BPH CTT technology. The data presented at the AUA showed that the compelling comparative value of our technologies is driven by both the low-cost of the procedure and the strong safety, durability and effectiveness. We believe both CTT and Prostiva will become more important to optimizing BPH care pathways as demand for cost-effective therapies continues to grow.”

 

 
 

 

As of June 30, 2014, the Company’s cash balance was $718,000 compared to $816,000 as of March 31, 2014, reflecting cash utilization of $98,000 in the fourth quarter. The cash utilization in the quarter includes the impact of approximately $80,000 in cash payments related to the restructuring that occurred in April 2014. In the fourth quarter of fiscal year 2013, the Company spent $2.8 million which included a $2.0 million payment to Medtronic as part of a debt restructuring agreement to pay off obligations deferred from earlier in that fiscal year. Net of the debt restructuring payment, the cash balances decreased $844,000 in the prior year period. The Company’s cash needs will be determined by a number of items including operating performance and the timing of annual royalty payments for Prostiva due and unpaid as of June 30, 2014. Royalty payments and other fees due Medtronic total $715,000 and are included in short-term liabilities as of June 30, 2014.

Regarding the amounts due and unpaid to Medtronic, “Urologix and Medtronic both share a sincere commitment to patients and urologists. We recognize Medtronic’s continuing rights under the agreements, and are working with Medtronic in our effort to restructure the business, both directly and through Medtronic’s engagement as an observer on our Board of Directors” stated Greg Fluet, Chief Executive Officer.

On a full year basis, the Company’s cash balance decreased $1.6 million in fiscal year 2014, compared to cash utilization of $3.7 million in fiscal year 2013, after adjusting cash balances for financing proceeds of $3.8 million and the receipt of $321,000 from the demutualization of an insurer. Including the financing proceeds and gain from the demutualization of an insurer, the Company’s cash balance increased $391,000 in fiscal year 2013.

Gross profit for the fourth quarter of fiscal year 2014 was $1.6 million, or 48.0% of revenue, compared to $1.9 million, or 45.5% of revenue, in the fourth quarter of fiscal year 2013. The increase in the gross margin rate is due to the fourth quarter fiscal year 2013 cost of goods including an impairment charge of $274,000 related to intangible assets acquired with the Prostiva product line. Excluding the impairment charge, gross margins would have decreased by approximately 4 percentage points driven primarily by product sales mix, lower production volumes and lower margins associated with our mobile service offering.

 

The Company performed our annual goodwill impairment test as of April 30, 2014, which included as part of the testing, fair valuing all of our assets and liabilities, including those obtained as part of the Prostiva acquisition. It was determined that the fair value of the Company could no longer support the carrying value of the goodwill acquired in that acquisition.   As a result, we recorded a $3.0 million non-cash goodwill impairment charge in our statements of operations. 

Total operating expense was $5.0 million for the fourth quarter of fiscal year 2014, which includes the impairment of goodwill resulting from the Prostiva acquisition of $3.0 million. Excluding the goodwill impairment charge, fourth quarter fiscal year 2014 operating expenses were $2.0 million, compared to operating expenses of $3.1 million in the fourth quarter of fiscal year 2013. The fourth quarter operating expense for fiscal year 2014 benefited from the restructuring of the Company announced on April 11, 2014.

 

For the fourth quarter of fiscal year 2014, Urologix reported a net loss of $3.5 million, or $0.17 per diluted share, compared to a net loss of $1.2 million, or $0.06 per diluted share, in the fourth quarter of fiscal year 2013.

 

 
 

 

For the fiscal year 2014 period ended June 30, 2014, revenues totaled $14.2 million, down 14.2% compared to revenues of $16.6 million in fiscal year 2013. The year-over-year decline in revenue was driven by similar declines in sales of Cooled ThermoTherapy (CTT) products and Prostiva Radio Frequency (RF) Therapy products.

 

Gross profit for fiscal year 2014 was $6.1 million, or 42.8% of sales. Gross profit was negatively affected by a $739,000 non-cash charge associated with the write down of Prostiva capital equipment inventory in the third quarter of fiscal year 2014. The write down was triggered by the low volume of sales of the capital equipment and does not affect the marketability of the product.

 

Total operating expense in fiscal year 2014 was $13.0 million. Excluding the $3.0 million goodwill impairment charge, operating expenses were $10.0 million in fiscal year 2014 compared to operating expenses of $12.1 million in fiscal year 2013. The Company reported a net loss of $7.6 million, or $0.36 per diluted share, for fiscal year 2014, compared to a net loss of $4.3 million, or $0.21 per diluted share, in the prior fiscal year period.

 

Earnings Call Information

 

Urologix will host a conference call with the financial community to discuss fiscal year 2014 fourth quarter and full year results on Tuesday, August 19, 2014 at 4:00 p.m. Central Daylight Time. To listen to the call, please dial 1-877-415-3180 and enter the Participant Passcode 30328726 at least 10 minutes prior to the call. A live webcast of the call will be available through the investor relations section of the Company’s website at www.urologix.com and available for replay approximately two hours after the completion of the call.

 

About Urologix

 

Urologix, Inc., based in Minneapolis, develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix’ Cooled ThermoTherapy™ produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva® RF Therapy System delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH symptoms. Both of these therapies provide safe, effective and lasting relief of the symptoms and obstruction due to BPH. Prostiva® is a registered trademark of Medtronic, Inc., used under license. All other trademarks are the property of Urologix.

 

If you’d like more information on this topic, please contact Greg Fluet at (763) 475-1400 or investor-relations@urologix.com or to learn more about Urologix and its products and services, visit their website at www.urologix.com.

 

The Urologix, Inc. logo is available at www.urologix.com/clinicians/resource-library.php.

 

 
 

 

Forward Looking Statements

 

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate” or “continue” or comparable terminology are intended to identify forward-looking statements. Such forward looking statements include, for example, the effectiveness of the Company’s sales and marketing strategies and organization, the Company’s future revenue and operating performance, or about the development and marketing of new products. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause the actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s Annual Report on Form 10-K for the year ended June 30, 2013 and other documents filed with the Securities and Exchange Commission.

 

Urologix Media Contact Urologix Investor Relations Contact
Susan Overby Greg Fluet
(763) 745-1540 (763) 475-1400
SOverby@urologix.com investor-relations@urologix.com

 

 

 

 

 

 
 

Urologix, Inc.

Statements of Operations

(Unaudited, in thousands, except per share data)

 

   Three Months Ended
June 30,
  Twelve Months Ended
June 30,
   2014  2013  2014  2013
Sales  $3,294   $4,184   $14,235   $16,590 
Cost of goods sold   1,711    2,279    8,142    8,407 
Gross profit   1,583    1,905    6,093    8,183 
                     
Costs and expenses:                    
Sales and marketing   1,011    2,080    5,850    7,719 
General and administrative   526    421    2,299    2,515 
Research and development   344    514    1,625    2,269 
Change in value of acquisition consideration       (79)   (105)   (447)
Impairment of goodwill   3,036        3,036     
Gain on demutualization               (321)
Impairment of identifiable intangible assets       160        160 
Medical device tax   51    65    223    106 
Amortization expense   23    26    95    104 
Total costs and expenses   4,991    3,187    13,023    12,105 
                     
Operating loss   (3,408)   (1,282)   (6,930)   (3,922)
Interest expense   (177)   (207)   (693)   (555)
Gain on debt extinguishment       206        206 
Foreign currency exchange gain/(loss)   (2)   2    (1)   (7)
Loss before income taxes   (3,587)   (1,281)   (7,624)   (4,278)
                     
Income tax expense/(benefit)   (62)   (34)   (16)   14 
Net loss  $(3,525)  $(1,247)  $(7,608)  $(4,292)
                     
Net loss per common sharebasic  $(0.17)  $(0.06)  $(0.36)  $(0.21)
                     
Net loss per common sharediluted  $(0.17)  $(0.06)  $(0.36)  $(0.21)
                     
Weighted average number of common shares outstandingbasic   21,299    20,909    21,219    20,703 
                     
Weighted average number of common shares outstandingdiluted   21,299    20,909    21,219    20,703 

 

 
 

 

Urologix, Inc.

Balance Sheets

(Unaudited, in thousands)

 

   June 30, 2014  June 30, 2013
ASSETS          
Current assets:          
Cash  $718   $2,290 
Accounts receivable, net   1,502    2,132 
Inventories   1,397    1,571 
Prepaids and other current assets   63    128 
Total current assets   3,680    6,121 
Property and equipment:          
Property and equipment   12,162    12,165 
Less accumulated depreciation   (11,691)   (11,430)
Property and equipment, net   471    735 
Other intangible assets, net   1,370    1,587 
Goodwill       3,036 
Long-term inventories   141    1,043 
Other assets   5    5 
Total assets  $5,667   $12,527 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY/(DEFICIT)          
Current liabilities:          
Accounts payable  $892   $628 
Accrued compensation   487    721 
Deferred income   6    5 
Short-term deferred acquisition payment   1,339    681 
Current portion of long-term debt   747     
Interest payable   322     
Other accrued expenses   499    602 
Total current liabilities   4,292    2,637 
           
Deferred tax liability       36 
Long-term deferred acquisition payment   3,730    4,026 
Long-term debt   4,586    5,333 
Other accrued liabilities   36    75 
Total liabilities   12,644    12,107 
           
Shareholders’ equity/(deficit):          
Common stock   209    208 
Additional paid-in capital   119,440    119,230 
Accumulated deficit   (126,626)   (119,018)
Total shareholders’ equity/(deficit)   (6,977)   420 
Total liabilities and shareholders’ equity/(deficit)  $5,667   $12,527 

 

 
 

Urologix, Inc.

Condensed Statements of Cash Flows

(Unaudited, in thousands)

 

   Fiscal Year Ended
June 30,
   2014  2013
Operating Activities:          
Net loss  $(7,608)  $(4,292)
           
Adjustments to reconcile net loss to net cash used for operating activities:          
Depreciation and amortization   587    674 
Impairment of identifiable intangible assets       434 
Impairment of goodwill   3,036     
Employee stock-based compensation expense   211    257 
Provision for bad debts   10    (23)
Prostiva inventory reserve   739     
Loss on disposal of assets   6    7 
Accretion expense on deferred acquisition payments   467    544 
Net adjustment to acquisition consideration   (105)   (447)
Gain on debt extinguishment       (206)
Deferred income taxes   (36)   1 
Change in operating assets and liabilities:          
Accounts receivable   620    23 
Inventories   267    (626)
Prepaids and other assets   65    162 
Accounts payable   264    1,760 
Accrued expenses and deferred income   (375)   (227)
Interest payable   322     
Net cash used for operating activities   (1,530)   (1,959)
           
Investing Activities:          
Purchases of property and equipment   (32)   (79)
Acquisition of business       (1,368)
Purchases of intellectual property   (10)   (32)
Net cash used for investing activities   (42)   (1,479)
           
Financing Activities:          
Proceeds from stock option exercises       15 
Issuance of common stock       3,814 
Net cash provided by financing activities       3,829 
           
Net increase /(decrease) in cash   (1,572)   391 
Cash:          
Beginning of year   2,290    1,899 
End of year  $718   $2,290 
           
Supplemental cash-flow information          
Income taxes paid during the period  $27   $17 
Net amount of inventory transferred to property and equipment  $70   $202 
Deferred acquisition payment and accounts payable transferred to long-term debt  $   $5,333 

 

 


The following information was filed by Urologix Inc (ULGX) on Wednesday, August 20, 2014 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Urologix Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Urologix Inc.

Continue

Assess how Urologix Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Urologix Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2014 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Balance Sheets
Balance Sheets (parenthetical)
Statements Of Cash Flows
Statements Of Operations
Statements Of Shareholders' Equity/(deficit)
Benefit Plan
Commitments And Contingencies
Commitments And Contingencies (narrative) (details)
Commitments And Contingencies (schedule Of Estimated Prostiva Payments) (details)
Commitments And Contingencies (schedule Of Future Minimal Annual Lease Commitments) (details)
Commitments And Contingencies (tables)
Deferred Income
Deferred Income (details)
Fair Value Measurements
Fair Value Measurements (narrative) (details)
Fair Value Measurements (reconciliation Of Contingent Consideration Liability) (details)
Fair Value Measurements (reconciliation Of Goodwill) (details)
Fair Value Measurements (reconciliation Of Long-lived Assets) (details)
Fair Value Measurements (tables)
Financing Arrangement
Financing Arrangement (details)
Gain On Demutualization
Gain On Demutualization (details)
Goodwill
Goodwill (details)
Income Taxes
Income Taxes (narrative) (details)
Income Taxes (reconciliation Of Statutory Tax Expense (benefit) To Actual Tax Expense (benefit)) (details)
Income Taxes (schedule Of Components Of Income Tax Expense (benefit)) (details)
Income Taxes (schedule Of Components Of Net Deferred Tax Assets And Liabilities)) (details)
Income Taxes (schedule Of Expiration Dates And Net Operating Loss Carryforwards And Credits) (details)
Income Taxes (tables)
Intangible Assets
Intangible Assets (future Amortization Expense Related To Net Carrying Amount Of Intangible Assets) (details)
Intangible Assets (narrative) (details)
Intangible Assets (schedule Of Intangible Assets) (details)
Intangible Assets (tables)
Liquidity
Liquidity (details)
Nature Of Business
Other Accrued Expenses
Other Accrued Expenses (details)
Other Accrued Expenses (tables)
Restructuring
Restructuring (narrative) (details)
Restructuring (schedule Of Restructuring Activity) (details)
Restructuring (tables)
Significant Accounting Policies
Significant Accounting Policies (narrative) (details)
Significant Accounting Policies (policy)
Significant Accounting Policies (schedule Of Allowance For Doubtful Accounts) (details)
Significant Accounting Policies (schedule Of Inventories) (details)
Significant Accounting Policies (schedule Of Product Warranty Liability) (details)
Significant Accounting Policies (schedule Of Property, Plant And Equipment) (details)
Significant Accounting Policies (schedule Of Shares Used In Earnings Per Share Computation) (details)
Significant Accounting Policies (tables)
Stock Options And Restricted Stock Awards
Stock Options And Restricted Stock Awards (amounts Recognized In Financial Statements Related To Stock-based Compensation) (details)
Stock Options And Restricted Stock Awards (assumptions Used To Estimate Fair Value Of Options Granted) (details)
Stock Options And Restricted Stock Awards (narrative) (details)
Stock Options And Restricted Stock Awards (summary Of Non-vested Options) (details)
Stock Options And Restricted Stock Awards (summary Of Non-vested Restricted Stock Activity) (details)
Stock Options And Restricted Stock Awards (summary Of Stock Option Activity By Exercise Price) (details)
Stock Options And Restricted Stock Awards (summary Of Stock Option Activity) (details)
Stock-based Compensation (tables)
Ticker: ULGX
CIK: 882873
Form Type: 10-K Annual Report
Accession Number: 0000897101-14-001320
Submitted to the SEC: Fri Sep 19 2014 4:08:02 PM EST
Accepted by the SEC: Fri Sep 19 2014
Period: Monday, June 30, 2014
Industry: Electromedical And Electrotherapeutic Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/ulgx/0000897101-14-001320.htm